Claim · claimSorter/cs-022

FDA approval of psilocybin-assisted therapy would make it broadly accessible to patients who need it

Education, not medical advice. Drafts and study material from an independent research library. Citations on this page were checked on Oct 13, 2026; claims in the body text and organizational sources are still under review. What was checked.

FDA approval of psilocybin-assisted therapy would make it broadly accessible to patients who need it

Refuted recorded as “Probably False” LSD: My Problem Child

The Australian experience after the world's first psychedelic therapy approval (February 2023) is the most relevant data point: treatment costs $25,000-35,000 AUD per patient with no insurance coverage, fewer than 100 psychiatrists authorized nationally by mid-2024, access almost exclusively to wealthy private patients. US approval without mandatory insurance coverage and reimbursement would produce a similar boutique market. Approval is necessary but not sufficient for broad access.

TGA Australia (2023); Australian Healthcare & Hospitals Association (2025)

Links for this item

Posts
No post is recorded for this item yet.
Source page
The sources for this item on RN Collins Selected Work
Long-form
The Australian Model: What Happens When a Country Actually Approves, the editorial draft this item belongs with
Gallery
See it in the gallery index
Project
About this library on RN Collins Selected Work
Corrections
Publication rules and the correction form

Course modules that use this claim

Drafts on the same book

Reading list for this book

NotebookLM packs on this book

Bridge pieces that use this book

Science annotations on this book

Then vs. Now comparisons on this book

Other pages in this library that link here